Senesco
Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced, that it has initiated preclinical lab studies at Mayo Clinic focused
on multiple myeloma. These studies will further test the ability of
Senesco's Factor 5A gene technology to up-regulate apoptosis of cancer
cells. Additionally, the studies will evaluate delivery molecules for
encapsulation of Factor 5A to enhance the time the gene will circulate in
the bloodstream before clearance by the body.
The data gathered from these animal experiments, together with the
results of other Factor 5A studies, will be reviewed to determine its
sufficiency for submission of a protocol to Mayo Clinic for human studies
and to the Food and Drug Administration for an Investigational New Drug
Application.
Previously, Senesco has announced the results of experiments performed
at Mayo Clinic on a human multiple myeloma cell line. In those experiments,
treatment with Factor 5A caused significant increase in apoptosis of the
cancer cells compared to the untreated cells.
About Senesco Technologies, Inc.
Senesco Technologies, Inc. is a U.S. biotechnology company,
headquartered in New Brunswick, NJ. Senesco has initiated preclinical
research to trigger or delay cell death in mammals (apoptosis) to determine
if the technology is applicable in human medicine. Accelerating apoptosis
may have applications to development of cancer treatments. Delaying
apoptosis may have applications to certain diseases inflammatory and
ischemic diseases. Senesco takes its name from the scientific term for the
aging of plant cells: senescence. Delaying cell breakdown in plants extends
freshness after harvesting, while increasing crop yields, plant size and
resistance to environmental stress. The Company believes that its
technology can be used to develop superior strains of crops without any
modification other than delaying natural plant senescence. Senesco has
partnered with leading-edge companies engaged in agricultural biotechnology
and earns research and development fees for applying its gene-regulating
platform technology to enhance its partners' products.
Certain statements included in this press release are forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Actual results could differ materially from such statements
expressed or implied herein as a result of a variety of factors, including,
but not limited to: the development of the Company's gene technology; the
approval of the Company's patent applications; the successful
implementation of the Company's research and development programs and joint
ventures; the success of the Company's license agreements; the acceptance
by the market of the Company's products; success of the Company's
preliminary studies and preclinical research; competition and the timing of
projects and trends in future operating performance, the Company's ability
to meet its funding milestones under its financing transaction, the
Company's ability to comply with the continued listing standards of the
AMEX, as well as other factors expressed from time to time in the Company's
periodic filings with the Securities and Exchange Commission (the "SEC").
As a result, this press release should be read in conjunction with the
Company's periodic filings with the SEC. The forward-looking statements
contained herein are made only as of the date of this press release, and
the Company undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.
Senesco Technologies, Inc.
senesco